BELAROUSSI, Yaniss; BOUTEILLER, Fanny; BELLERA, Carine; PASQUIER, David; PEROL, Maurice; DEBIEUVRE, Didier; FILLERON, Thomas; GIRARD, Nicolas; SCHOTT, Roland; MATHOULIN-PELISSIER, Simone; MARTIN, Anne-Laure; COUSIN, Sophie

doi:10.1038/s41598-023-36623-1

BELAROUSSI, Yaniss
Bordeaux population health [BPH]

BOUTEILLER, Fanny

BELLERA, Carine
Bordeaux population health [BPH]

Langue

Article de revue

Ce document a été publié dans

Scientific Reports. 2023-06-13, vol. 13, n° 1, p. 9584

Résumé en anglais

Treatment of metastatic non-small cell lung cancer (mNSCLC) has been modified due to the development of immunotherapy. We assessed survival outcomes (overall [OS] and progression-free [rwPFS] survivals, time-to-next-treatment [TNT]) in mNSCLC patients after first-line immunotherapy and chemotherapy in real-life settings. Association between rwPFS and TNT, two candidate surrogate endpoints (SE), with OS was assessed. This retrospective multi-center study uses data from patients included in the Epidemio-Strategy Medico-Economic program with mNSCLC over 2015-2019. The impact of treatment on rwPFS/OS was evaluated with Cox models. Individual-level associations between SE and OS were estimated with an iterative multiple imputation approach and joint survival models. The population included 5294 patients (63 years median age). Median OS in immunotherapy group was 16.4 months (95%CI [14.1-NR]) and was higher than in chemotherapy group (11.6 months; 95%CI [11.0-12.2]). Improved OS was observed for the immunotherapy group after 3 months for subjects with performance status 0-1 (HR = 0.59; 95%CI [0.42-0.83], p < 0.01). The associations between rwPFS and TNT with OS were close ([Formula: see text]=0.57). Results emphasized a survival improvement with immunotherapy for patients in good health condition. There was moderate evidence of individual-level association between candidate SE and OS.< Réduire

Mots clés en anglais

Humans

Carcinoma

Non-Small-Cell Lung

Lung Neoplasms

Immunotherapy

Patients

Time-to-Treatment

URI

https://oskar-bordeaux.fr/handle/20.500.12278/184332

DOI

http://dx.doi.org/10.1038/s41598-023-36623-1

Unités de recherche

Bordeaux Population Health Research Center (BPH) - UMR 1219

Voir/Ouvrir

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Survival outcomes of patients with metastatic non-small cell lung cancer receiving chemotherapy or immunotherapy as first-line in a real-life setting.

Langue

Ce document a été publié dans

Résumé en anglais

Mots clés en anglais

URI

DOI

Unités de recherche